No Data
No Data
No Data
No Data
No Data
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial resul
PR NewswireMay 1 19:05
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on...
PR NewswireApr 24 19:05
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Seeking AlphaApr 23 22:29
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 28%
REGENXBIO Inc. (NASDAQ:RGNX) shares have retraced a considerable 28% in the last month, reversing a fair amount of their solid recent performance. The drop over the last 30 days has capped off a to
Simply Wall StApr 19 18:29
Regenxbio(RGNX.US) Officer Sells US$272.87K in Common Stock
$Regenxbio(RGNX.US)$ Officer Mills Kenneth T. sold 15,000 shares of common stock on Apr 15, 2024 at an average price of $18.1914 for a total value of $272.87K.Source: Announcement What is statement of
Futu NewsApr 18 05:48
REGENXBIO Is Maintained at Buy by Stifel
REGENXBIO Is Maintained at Buy by Stifel
Dow JonesApr 13 00:03
No Data
No Data